Zacks names Neurocrine Biosciences Bull of the Day, Ryanair Bear of the Day

Analyst

โดย Zacks Investment Research·Read original

Summary · why it matters

Zacks Equity Research has named Neurocrine Biosciences as the Bull of the Day and Ryanair Holdings as the Bear of the Day. Neurocrine earned a Zacks Rank #1 (Strong Buy) after analysts raised earnings estimates across all major periods over the last 60 days, with current-quarter EPS jumping 23.6% to $2.25 and full-year EPS rising 18.4% to $9.47. The company's flagship drug INGREZZA generated $2.86 billion in 2025 revenue, up 22% year over year, and management guided for $2.7 billion to $2.8 billion in INGREZZA sales in 2026. Ryanair, meanwhile, landed a Zacks Rank #5 (Strong Sell) as analysts slashed profit forecasts following management's cautious summer fare outlook, with fiscal 2027 EPS estimates dropping 24% over 90 days to $4.25. The airline cited softening ticket prices, rising operating costs, and limited earnings visibility.